| human | Q5 |
| P6178 | Dimensions author ID | 010536430723.39 |
| P2163 | FAST ID | 1574531 |
| P213 | ISNI | 0000000115878420 |
| P244 | Library of Congress authority ID | n2002152037 |
| P8189 | National Library of Israel J9U ID | 987007381385305171 |
| P691 | NL CR AUT ID | xx0256897 |
| P1207 | NUKAT ID | n2011162917 |
| P496 | ORCID iD | 0000-0002-6103-7056 |
| P7293 | PLWABN ID | 9810685566005606 |
| P1153 | Scopus author ID | 25943775400 |
| P214 | VIAF ID | 250487127 |
| P10832 | WorldCat Entities ID | E39PBJcgCCH3PTjmb8HPBQPWjC |
| P734 | family name | Isaacs | Q16871090 |
| Isaacs | Q16871090 | ||
| Isaacs | Q16871090 | ||
| P101 | field of work | medicine | Q11190 |
| immunology | Q101929 | ||
| rheumatology | Q327657 | ||
| P735 | given name | John | Q4925477 |
| John | Q4925477 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | physician | Q39631 |
| researcher | Q1650915 | ||
| rheumatologist | Q5997943 | ||
| immunologist | Q12119633 | ||
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P21 | sex or gender | male | Q6581097 |
| Q92931968 | "Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis |
| Q60061979 | 10 years of therapeutic advances in the rheumatic diseases |
| Q36094049 | A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. |
| Q35875673 | A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome |
| Q50796127 | A negative feedback loop mediated by STAT3 limits human Th17 responses. |
| Q40400372 | A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation |
| Q46095815 | A novel paradigm for dendritic cells as effectors of cartilage destruction. |
| Q56462138 | A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis |
| Q52852039 | A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. |
| Q60061989 | A randomised, controlled, double blinded study of ultrasound guided corticosteroid joint injection in patients with inflammatory arthritis |
| Q60062004 | A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans |
| Q52853353 | Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. |
| Q31151181 | Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis |
| Q36293513 | Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease |
| Q60061997 | Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells |
| Q34896371 | Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. |
| Q60061993 | Animal models in infection and inflammation - chance and necessity |
| Q37964318 | Anti-TNF therapy |
| Q60061999 | Anti-TNFα Therapy Modulates the Phenotype of Peripheral Blood CD4+T Cells in Patients with Posterior Segment Intraocular Inflammation |
| Q37505420 | Antibody engineering to develop new antirheumatic therapies |
| Q34184314 | Application of differential display to immunological research. |
| Q57323704 | Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF B signalling pathways |
| Q42564764 | Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis |
| Q37054390 | Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response |
| Q64109926 | Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39 |
| Q37000109 | Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis |
| Q57306851 | Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis |
| Q37517575 | Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. |
| Q37604510 | Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis |
| Q36085007 | Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up |
| Q60061978 | Bcl-3 in CD4+ T Cell-Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al |
| Q92974083 | Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic |
| Q56975651 | Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
| Q37909907 | Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? |
| Q36694805 | Biologic therapies in rheumatology: lessons learned, future directions |
| Q38592363 | Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. |
| Q49376742 | CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification. |
| Q57173903 | CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy |
| Q36665428 | CMV seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians: results from the Newcastle 85+ study |
| Q28109583 | Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23 |
| Q34454531 | Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials |
| Q48092147 | Clinical trials of biosimilars should become more similar |
| Q36832755 | Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis |
| Q41447431 | Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. |
| Q31112066 | Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. |
| Q52844225 | Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. |
| Q36633196 | Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study S |
| Q37398076 | Current concepts in the pathogenesis of early rheumatoid arthritis |
| Q38666239 | Cytokines in rheumatoid arthritis - shaping the immunological landscape |
| Q35242453 | Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. |
| Q55089799 | Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus. |
| Q91823360 | Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists |
| Q34006506 | Detection of Mycobacterium tuberculosis group organisms in human and mouse joint tissue by reverse transcriptase PCR: prevalence in diseased synovial tissue suggests lack of specific association with rheumatoid arthritis |
| Q37383419 | Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. |
| Q36995849 | Determination of thymic function directly from peripheral blood: a validated modification to an established method. |
| Q37701864 | Development of dendritic cell-based immunotherapy for autoimmunity |
| Q37023870 | Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis |
| Q41754216 | Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells |
| Q36907659 | Disease activity and cognition in rheumatoid arthritis: an open label pilot study |
| Q50585017 | Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. |
| Q37705181 | Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers. |
| Q52009888 | Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. |
| Q96171120 | EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 |
| Q46068649 | Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis |
| Q37689966 | Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis |
| Q46467386 | Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial |
| Q60061986 | Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis |
| Q56420714 | Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q45370040 | Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis |
| Q35654020 | Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial |
| Q50980583 | Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. |
| Q47784149 | Fc gamma receptors are critical modulators of inflammation within the synovium: comment on the article by Blom et al. |
| Q73092745 | Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups |
| Q34123499 | FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy |
| Q47666819 | Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. |
| Q41180997 | Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. |
| Q34134975 | Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients |
| Q28489093 | Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis |
| Q24628710 | Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls |
| Q34886162 | Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci |
| Q60061980 | Genotyping in rheumatoid arthritis: a game changer in clinical management? |
| Q37604498 | High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort |
| Q59042851 | High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis |
| Q34518941 | Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. |
| Q60062009 | Humanised monoclonal antibody therapy for rheumatoid arthritis |
| Q36577401 | IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis |
| Q37518302 | Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies |
| Q50960730 | Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. |
| Q35881647 | Immunotherapy of rheumatoid arthritis. |
| Q35102134 | Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort |
| Q34130318 | Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis |
| Q95833967 | In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis |
| Q35311054 | Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7 |
| Q41994013 | Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. |
| Q35840716 | Integrated safety in tocilizumab clinical trials |
| Q36439978 | Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples |
| Q51785508 | Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. |
| Q24310184 | Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment |
| Q42110748 | LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. |
| Q96016711 | Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs |
| Q60061976 | Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC) |
| Q48171918 | Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect! |
| Q60062002 | Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation |
| Q60062007 | Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy |
| Q38617064 | Lost in space: design of experiments and scientific exploration in a Hogarth Universe |
| Q39338146 | Low-strength T-cell activation promotes Th17 responses. |
| Q60061998 | Management of rheumatoid arthritis in primary care—an educational need? |
| Q38991972 | Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. |
| Q39775657 | Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells |
| Q60062010 | Mesangial IgA Disease with Crescent Formation During Pregnancy: Postpartum Treatment with Immunosuppression |
| Q49403463 | Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization |
| Q28596281 | Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies |
| Q39713867 | Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. |
| Q37073761 | Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes |
| Q47343514 | Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis |
| Q38126008 | Novel immunotherapies for rheumatoid arthritis. |
| Q53131122 | Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? |
| Q35552816 | Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis. |
| Q37856146 | Pathophysiology of rheumatoid arthritis |
| Q40407272 | Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research |
| Q101124613 | Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score |
| Q55344794 | Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis. |
| Q53335115 | Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. |
| Q37690108 | Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? |
| Q37067150 | Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. |
| Q60061987 | Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months |
| Q60062005 | Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H |
| Q37200651 | Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort |
| Q43696497 | Profound invariant natural killer T-cell deficiency in inflammatory arthritis. |
| Q47748916 | Progression-seeking bias and rational optimism in research and development |
| Q40565049 | Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): c |
| Q27318199 | Prospects for therapeutic tolerance in humans |
| Q38261841 | R&D productivity rides again? |
| Q35998928 | RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial |
| Q21256663 | Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions |
| Q37471303 | Regulatory T cells and autoimmunity |
| Q36189976 | Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort |
| Q60061981 | Retrospective analysis of the role of serum vitamin D in early rheumatic disease |
| Q35544546 | Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study |
| Q36839197 | Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy |
| Q36011107 | Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy |
| Q38373629 | Rheumatoid arthritis: an evolutionary force in biologics |
| Q39084894 | Rheumatoid arthritis: from palliation to remission in two decades |
| Q60061985 | Rheumatology Conference Highlights |
| Q112291812 | Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach |
| Q39998781 | Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. |
| Q38284201 | Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects. |
| Q60061988 | Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort |
| Q96302073 | Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs |
| Q35859428 | Stem cell transplantation for autoimmune disorders. Immune reconstitution |
| Q47235759 | Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. |
| Q40891825 | Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. |
| Q39431367 | Synovial tissue research: a state-of-the-art review |
| Q59041025 | Synovial tissue research: a state-of-the-art review |
| Q36870412 | T cell immunomodulation--the Holy Grail of therapeutic tolerance |
| Q41856587 | T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice |
| Q40095092 | Targeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases? |
| Q40331977 | Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecy |
| Q50467012 | Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. |
| Q60061983 | The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis |
| Q52839665 | The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. |
| Q34042702 | The Darwin Awards: sex differences in idiotic behaviour |
| Q47355032 | The RA-MAP Consortium: a working model for academia-industry collaboration. |
| Q44508845 | The changing face of rheumatoid arthritis: sustained remission for all? |
| Q60061995 | The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: Comment on the article by van der Helm-van Mil et al |
| Q46919820 | The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. |
| Q47427257 | The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. |
| Q57753442 | The need for personalised medicine for rheumatoid arthritis |
| Q33731299 | The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort |
| Q56420835 | The relationship between pityriasis rubra pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis factor immunotherapy |
| Q38068691 | The role of biosimilars in the treatment of rheumatic diseases |
| Q52851165 | The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). |
| Q37173126 | Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q60061990 | Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses |
| Q60061996 | Thymic function and immune senescence in juvenile idiopathic arthritis: Comment on the article by Prelog et al |
| Q60061984 | Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis |
| Q34338355 | Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? |
| Q38800903 | Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1. |
| Q38674722 | Traceless Cleavage of Protein-Biotin Conjugates under Biologically Compatible Conditions |
| Q49151897 | Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis |
| Q60061991 | Translating cutting edge science into novel and effective therapies |
| Q37781916 | Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases |
| Q30494071 | Treatment of stiff person syndrome with rituximab. |
| Q38124277 | Treg cells in rheumatoid arthritis: an update |
| Q60061992 | Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis |
| Q38975794 | Unique TCR beta-subunit variable gene haplotypes in Africans |
| Q41535327 | What can rheumatologists learn from translational cancer therapy? |
| Q60061982 | Why is it hard to terminate failing projects in pharmaceutical R&D? |
| Q37588725 | Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? |
Search more.